Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV.

J Clin Invest. 2000 Dec;106(12):1489-99.

2.

Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.

3.
5.

Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism.

Poirier J.

Ann N Y Acad Sci. 2000;924:81-90. Review.

PMID:
11193807
6.

Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Deane R, Zlokovic BV.

Curr Alzheimer Res. 2007 Apr;4(2):191-7. Review.

PMID:
17430246
7.

Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.

Donahue JE, Johanson CE.

J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70. doi: 10.1097/NEN.0b013e31816a0dc8. Review. Erratum in: J Neuropathol Exp Neurol. 2008 Jun;67(6):634.

8.

Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer's disease.

Pflanzner T, Kuhlmann CR, Pietrzik CU.

Curr Alzheimer Res. 2010 Nov;7(7):578-90. Review.

PMID:
20704558
9.

The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery.

Sharma HS, Castellani RJ, Smith MA, Sharma A.

Int Rev Neurobiol. 2012;102:47-90. doi: 10.1016/B978-0-12-386986-9.00003-X. Review.

PMID:
22748826
10.

Clearing amyloid through the blood-brain barrier.

Zlokovic BV.

J Neurochem. 2004 May;89(4):807-11. Review.

11.

New therapeutic targets in the neurovascular pathway in Alzheimer's disease.

Zlokovic BV.

Neurotherapeutics. 2008 Jul;5(3):409-14. doi: 10.1016/j.nurt.2008.05.011. Review.

12.

Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.

Martiskainen H, Haapasalo A, Kurkinen KM, Pihlajamäki J, Soininen H, Hiltunen M.

Expert Opin Ther Targets. 2013 Jul;17(7):781-94. doi: 10.1517/14728222.2013.789862. Epub 2013 Apr 11. Review.

PMID:
23573918
13.

Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.

Sagare AP, Bell RD, Zlokovic BV.

Cold Spring Harb Perspect Med. 2012 Oct 1;2(10). pii: a011452. doi: 10.1101/cshperspect.a011452. Review.

14.

[Blood-brain barrier and Alzheimer's disease].

Kuwahara H, Nishida Y, Yokota T.

Brain Nerve. 2013 Feb;65(2):145-51. Review. Japanese.

PMID:
23399672
15.

Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain.

Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA.

J Neurochem. 2010 Dec;115(5):1077-89. doi: 10.1111/j.1471-4159.2010.07002.x. Epub 2010 Oct 5. Review.

16.

Apolipoprotein E receptor pathways in Alzheimer disease.

Schmidt V, Carlo AS, Willnow TE.

Wiley Interdiscip Rev Syst Biol Med. 2014 May-Jun;6(3):255-70. doi: 10.1002/wsbm.1262. Epub 2014 Mar 6. Review.

PMID:
24604742
17.

Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Sagare AP, Deane R, Zlokovic BV.

Pharmacol Ther. 2012 Oct;136(1):94-105. doi: 10.1016/j.pharmthera.2012.07.008. Epub 2012 Jul 20. Review.

18.

Apolipoprotein E receptors: linking brain development and Alzheimer's disease.

Herz J, Beffert U.

Nat Rev Neurosci. 2000 Oct;1(1):51-8. Review.

PMID:
11252768
19.

Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease.

Sagare AP, Bell RD, Zlokovic BV.

J Alzheimers Dis. 2013;33 Suppl 1:S87-100. Review.

20.

Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Erickson MA, Banks WA.

J Cereb Blood Flow Metab. 2013 Oct;33(10):1500-13. doi: 10.1038/jcbfm.2013.135. Epub 2013 Aug 7. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk